Effect of hormone replacement therapy on the cardiovascular system;Vliv hormonální substituční terapie na kardiovaskulární systém

Ceska Gynekologie

Volumn 67, Issue 5, 2002, Pages 285-293

  Fait, T ^a   Malkova J ^a   Zivny J ^a  

^a CHARLES UNIVERSITY   (Czech Republic)

Author keywords

Cardiovascular disease; Hormone replacement therapy

Indexed keywords

ANDROGEN; C REACTIVE PROTEIN; CELL ADHESION MOLECULE; CONJUGATED ESTROGEN; ESTRADIOL; ESTRADIOL VALERATE; ESTROGEN; GESTAGEN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HOMOCYSTEINE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEDROXYPROGESTERONE ACETATE; RALOXIFENE; TIBOLONE; TRIACYLGLYCEROL;

BODY DISTRIBUTION; BODY FAT; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; DATA BASE; DRUG ANTAGONISM; ESTROGEN THERAPY; FEMALE; HORMONE SUBSTITUTION; HUMAN; HYPERTRIGLYCERIDEMIA; INSULIN RESISTANCE; ISCHEMIC HEART DISEASE; LIPOPROTEIN BLOOD LEVEL; MEDICAL LITERATURE; MEDICAL SCHOOL; MEDLINE; REVIEW; TRIACYLGLYCEROL BLOOD LEVEL;

CARDIOVASCULAR DISEASES; CORONARY DISEASE; ESTROGEN REPLACEMENT THERAPY; FEMALE; HUMANS; LIPIDS; MYOCARDIAL ISCHEMIA; RISK FACTORS;

EID: 0036397220     PISSN: 12107832     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (71)

1. Assmann, G., Schulte, H., von Eckardstein, A.: Hypertriglyceridemia and elevated Lp(a) are risk factors for major coronary events in middle-aged men. Am. J. Cardiol., 77, 1996, s. 1179-1184.
2. Baal, W. M. et al.: Short term HRT: redused plasma levels of soluble adhesion molecules. Eur. J. Clin. Invest., 29, 11, 1999, s. 913-921.
3. Baal, W. M. et al.: Cardiovascular disease risk and HRT. In: Baal W. M.: HRT: beneficial as well as adverse effect on atherothrombotic risk? Vrije Universiteit, Amsterdam 1999, s. 15-52.
4. Bhathena, R. K., Ankleseria, B. S., Ganatra, A. M.: The treatment of hypertriglyceridaemia in menopausal women with transdermal oestradiol therapy. Br. J. Obstet. Gynecol., 106, 9, 1999, s. 980-982.
5. Burdová, M., Kancheva, R., Hill, H.: Results of a long-term study in hormone replacement therapy with Klimonorm. Drugs of today, 2001, 37, Suppl C, s. 23-29.
6. Busch, T. L. et al.: Cardiovascular mortality and noncontraceptive use of estrogen in women. Circulation, 75, 1987, s. 1102-1109.
7. Cagnacci, A. et al.: Effects of low doses of transdermal 17β-estradiol on carbohydrate metabolism in postmenopausal women. J. Clin. Endocrinol. Metab., 74, 1992, s. 1396-1400.
8. Cífková, R.: Diskrepance mezi observačními a intervenčními studiemi u HRT. 4. kongres o ateroskleróze, Špindleru̇v Mlýn 2000.
9. Colditz, G. A. et al.: Menopause and the risk of coronary heart disease in women. N. Engl. J. Med., 316, 1987, s. 1105-1110.
10. Collins, R., Beale, C. M.: The cardioprotective role of HRT - a clinical update. Partheon Publishing, London 1996, 60s.
11. Crook, D.: HRT choices for women with hypertriglyceridemia. In: Whitehead M.: The prescriber's guide to HRT. Partheon Publishing, London 1998, s. 183-191.
12. Cushman, M. et al.: Effect of postmenopausal hormones on inflammation-sensitive proteins. Circulation, 100, 7, 1999, s. 717-722.
13. Češka, R.: Cholesterol a ateroskleróza. Léčba hyperlipidémií, Maxdorf, Praha 1999, 226 s.
14. Denke, M. A.: Effect of continuous combine HRT on lipid levels in hypercholesterolemic postmenausal women. Am. J. Med., 1995, 99. s. 29-35.
15. Donát, J.: Lapidemia and BMD as indication of HRT selection. FEMS, Praha 2000.
16. Donát, J.: Hormonálni substitučni terapie. DoMeNa, Hradec Králové 1999, 192 s.
17. Espeland, M. A. et al.: ERT and progression of intimalmedial thickness in the carotid arteries of postmenopausal women. Am. J. Epidemiol., 142, 1995, s. 1011-1019.
18. Fak, A. S., Erenus, M., Tezear, H. et al.: Effects of simvastatin alone or in combination with continuous combine HRT on serunt lipid levels in hypercholesteroleic post-menopausal women. Eur. Heart. J., 2000, 21, s. 190-197.
19. Folsom, A. R. et al.: Population correlates of plasma fibrinogen and factor VII, putative cardiovascular risk factors. Atherosclerosis. 91, 1991, s. 191-205.
20. Gebara, O. C. E. et al.: Association between increased estrogen status and increased fibrinolytic potential in the Framingham Offspring study. Circulation. 91, 1995, s. 1952-1958.
21. Glefand, M. et al.: Conjugated estrogens combined with sequential dydrogesterone or MPA in postmenopausal women. Menopause 4, 1997, s. 10-18.
22. Godsland, I. F., Wynn, V., Crook, D. Miller, N. E.: Sex, plasma lipoproteins and atherosclerosis. Am. Heart J. 114, 1987, s. 1467-503.
23. Godsland, I. F. et al.: Insulinh resistance, secretion and elimination in postmenopausal women receiving oral or transdermal HTRT. Metabolism, 42, 1993, s. 846-853.
24. Graser, T. et al.: Dienogest as a progestin for HRT. Drugs of Today, 35 (Suppl. C), 1999, s. 115-126.
25. Grodstein, F., Stampfer, M. J.: Selection bias and studies of HRT. European consensus development conference. Montreux 1996.
26. Grodstein, F.: HRT and cardiovascular risk: the Nurses Health Study. FEMS, Prague 2000.
27. Grodstein, F. et al.: Postmenopausal estrogen and progestin use and the risk of cardiovascular disease. N. Engl. J. Med., 335, 1996, s. 453-461.
28. Gruehow, H. W., Anderson, A. J., Barhoriah, J. J., Sulocinski, K. A.: Postmenopausal use of estrogen and occlusion of coronary arteries. Am. Heart J., 115, 1988, s. 954-963.
29. Haarbo, J. et al.: Postmenopausal HRT prevents central distribution of body fat after menopause. Metabolism, 40, 1991, s. 1323-1326.
30. Hemminki, E., McPherson, K.: Impact of postmenopausal hormone therapy on cardiovascular events and cancer. BMJ, 315, 1997, s, 149-153.
31. Henderson, B. E., Paganini-Hill, A., Ross, R. K.: Decreased mortality in user of ERT. Arch. Intern Med., 151, 1991, s. 269-277.
32. Herrington, D. et al.: Effects of ERT on progression of coronary-artery atherosclerosis. N. England J. Med., 343, 2000, s. 522-529.
33. Hirvonen, E., Elliesen, J., Schmidt-Gollwitzer, K.: Compararison of two hormone replacement regimens - influence on lipoproteins and bone mineral content. Maturitas, 12, 1990, s. 127-136.
34. Hulley, S. et al.: Randomised trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. JAMA, 280, 1998, s. 605-613.
35. Kennedy, G., McLaren, M., Belch, J., Seed, M.: Elevated levels of sE-selectin in postmenopausal females are decreased by HRT to levels observed in pre-menopausal females. Thromb. Haemostat., 82, 1999, s. 1433-1436.
36. Keys, A. et al.: The diet and 15 years mortality in the seven countries study. Am. J. Epidemiol., 124, 1986, s. 903-915.
37. Koh, K. K. et al.: Vascular effects of estrogen and cholesterol-lowering therapies in hypercholesterolemic postmenopausal women. Circulation, 99, 1999, s. 354-356.
38. Kvasnička, J., jr., Živný, J.: Změny sérové koncentrace CRP a solubilních cytoadhesivnieh molekul E-selectinu a ICAM-1 po transdermální substituci 17β-estradiolem. Čes. Gynek., 66, 2001, 3, s. 161-165.
39. Ley, G. J., Lees, B., Stevenson, J. C.: Sex and menopause-associated changes in body-fat distribution. Am. J. Clin. Nutr., 55, 1992, s. 950-954.
40. Magnes, R. R., Rosenfeld, C. R.: Local and systemic estradiol, effects on uterine and systemic vasodilatation. Am. J. Physiol., 256, 1989, s. 536-542.
41. Málková, J.: Aktuální pohled na postavení ERT/HRT v prevenci kardiovaskulárních chorob. II. celostatní sjezd SSG ČR, 26-28, 5, 2000, Praha.
42. Málková, J., Andél, M.: HRT a prevence kardiovaskulárních chorob u postmenopausálních źen. Klimakt. Medicina., 2, 1, 1996, s. 39-42.
43. Manwaring, P., Morfis, L., Diamond, T., Howes, L. G.: The effects of hormone replacement therapy on plasma lipids in type II diabetes. Maturitas, 34, 2000, s. 239-247.
44. Mijatovic, V. et al.: Postmenopausal oral 17β-estradiol continuously combined with dydrogesterone reduces fasting serum homocysteine levels. Fertil. Steril., 69, 1998, s. 876-882.
45. Mijatovic, V.: Postamenopausal HRT and cardiovascular risk markers Lp(a) and homocystein. University hospital Vrije, Amsterdam 1999, 136 s.
46. Moore, R. A.: Livial: review of clinical studies. BJOG, 106, Suppl. 19, 1999, 21 s.
47. Nabel, E. G.: Coronary heart disease in women - an ounce of prevention. N. Engl. J. Med., 313, 2000, 572 s.
48. Newton, K. M. et al.: ERT and prognosis after first myocardial infarction. Am. J. Epid., 145, 1997, s. 269-277.
49. Pavelieu, F., Paveliu, S., Greabu, M.: Lipid profile in perimenopausal women with dyslipidemia under HRT. FEMS, Prague 2000.
50. Payer, J. et al.: Serum lipids and BMD before and after HRT. Klim. Med., 2, 1997, s. 34-36.
51. Pines, A. et al.: Menopause-reduced changes in Doppler-derived parameters of aortic flow in healthy women. Am. J. Cardiol., 69, 1992, s. 1101-1106.
52. th European Congress on Menopause, Kopenhagen 2000.
53. Ridker, P. M. et al.: C-reaktive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N. Engl. J. Med., 312, 2000, s. 836-843.
54. th European Congress on Menopause, Kopenhagen 2000.
55. th European Congress on Menopause, Kopenhagen 2000.
56. th European Congress on Menopause, Kopenhagen 2000.
57. Scarabin, P. Y. et al.: Factor VII activation and menopausal status. Thrombosis Res., 57, 1990, s 227-234.
58. Soma, M. et al.: Plasma Lp(a) concentration after estrogen and progestagen in postmenopausal women. Lancet. 337, 1991, 612 s.
59. Stamler, J. et al.: Is relationship between serum cholosterol and risk of premature death from coronary heart disease continuous and graded? JAMA, 256, 1986, s. 2823-2828.
60. Steingart, R. M., Packer, M., Hamm, P. et al.: Sex diffirences in the management of coronary artery disease. N. Engl. J. Med,. 325/1991, s. 226-230.
61. Stevenson, J. C. et al.: HRT and the cardiovascular system nonlipid effects. Drugs 47, Suppl 2, 1994, s. 35-41.
62. Sullivan, J. M. et al.: Estrogen replacement and coronary artery disease. Arch. Intern. Med., 150, 1990, s. 2557-2562.
63. Sullivan, J. M. et al.: Postmenopausal estrogen use and coronary atherosclerosis. Ann. Intern. Med., 108, 1988, s. 358-363.
64. Simon, J.: Chronické formy ICHS. Diagnóza, 14, 2000, s. 5-6.
65. The Writing Group for the PEP1 Trial: Effect of estrogen or estrogen/progestin regimens on heart disease factors in postmenopausal women. JAMA, 273, 1995, s. 199-208.
66. Van de Mooren, M. J. et al.: HRT may reduce high serum homocystein in postmenopausal women. Eur J. Clin. Invest., 24, 1995, s. 733-736.
67. Vaverková, H.: HRT a kardiovaskulární riziko. 4. kongres o ateroskluróze. Spindlerüv Mlýn 2000.
68. Walton, C. et al.: The effects of the menopause on insulin sensitity, secretion and elimination in non-obese, healthy women. Eur. J. Clin. Invest., 23, 1993, s. 466-473.
69. Walsh, B. W. et al.: Effects of postmenopausal estrogen replacement on the concentrations and metabolism of plasma lipoproteins. N. Engl. J. Med., 325, 1991, s. 1196-1201.
70. Walsh,B. W. et al.: Effect of raloxifene on serum lipids and coagulation factors in healthy postmenopausal women. JAMA, 279, 1998, s. 1445-1451.
71. Wouters, M. G. A. J. et al.: Plasma homocystein and menopausal status. Eur. J. Clin. Invest., 25, s. 801-805.